Luo Yumei, Jiang Wenling, Xu Danyan, Jiang Deqian
Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha 410011; Department of Cardiology, Longgang District People's Hospital of Shenzhen, Shenzhen 518172,China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Jul;38(7):681-5. doi: 10.3969/j.issn.1672-7347.2013.07.005.
To observe the effect of pioglitazone on carotid artery intima-media thickness (IMT) and plaque-positive rate in patients with metabolic syndrome, and to find a new way to improve arterial remodeling in patients with metabolic syndrome.
Patients with metabolic syndrome were randomly divided into a control group (n=60) and a pioglitazone group (n=61). All subjects received basic therapeutic measures, i.e, appropriate medication to control blood pressure, blood sugar and cholesterol. Pioglitazone (15 mg/d) was given to patients in the pioglitazone group, and placebo (vitamin C) in the control group for 24 weeks. Color doppler ultrasound was used to measure carotid artery IMT and plaque-positive rate of patients in the 2 groups after the intervention. Japan's Hitachi 7600-020 automatic biochemical analyzer was used to measure fasting serumal triglycerides, total cholesterol, high density lipoprotein cholesterol, low-density lipoprotein cholesterol, free fatty acids, fasting blood glucose, 2-hour postprandial glucose and liver and kidney function, etc. The differences between groups after the intervention were analyzed and compared in IMT, plaque-positive rate and all blood biochemical indicators.
After the intervention, compared with the control group, carotid artery plaque-positive rate and the levels of triglyceride and free fatty acid decreased in the pioglitazone group (P<0.05), but there was no difference in IMT of carotid artery and other blood biochemical indicators between the 2 groups (P>0.05).
Pioglitazone intervention can significantly improve pathologic artery remodeling, and it can more effectively inhibit the arterial plaque-formation than basic therapeutic measures in patients with metabolic syndrome.
观察吡格列酮对代谢综合征患者颈动脉内膜中层厚度（IMT）及斑块阳性率的影响，探寻改善代谢综合征患者动脉重塑的新方法。
将代谢综合征患者随机分为对照组（n = 60）和吡格列酮组（n = 61）。所有受试者均接受基本治疗措施，即使用适当药物控制血压、血糖和胆固醇。吡格列酮组患者给予吡格列酮（15 mg/d），对照组给予安慰剂（维生素C），疗程24周。干预后采用彩色多普勒超声测量两组患者的颈动脉IMT及斑块阳性率。使用日本日立7600 - 020全自动生化分析仪检测空腹血清甘油三酯、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、游离脂肪酸、空腹血糖、餐后2小时血糖及肝肾功能等。对干预后两组在IMT、斑块阳性率及所有血液生化指标方面的差异进行分析比较。
干预后，吡格列酮组颈动脉斑块阳性率及甘油三酯和游离脂肪酸水平较对照组降低（P < 0.05），但两组颈动脉IMT及其他血液生化指标差异无统计学意义（P > 0.05）。
吡格列酮干预可显著改善代谢综合征患者的病理性动脉重塑，且比基本治疗措施更有效地抑制动脉斑块形成。
